Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hackensack Meridian Health
Case Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Washington University School of Medicine
Fate Therapeutics
MEI Pharma, Inc.
Brown University
SymBio Pharmaceuticals
Gilead Sciences
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Swiss Cancer Institute
Wake Forest University Health Sciences
Alliance for Clinical Trials in Oncology
Milton S. Hershey Medical Center
UNC Lineberger Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
National Institutes of Health Clinical Center (CC)
Mayo Clinic